Can I read Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial on EtoBox?

Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial by Keunchil Park; Mustafa Özgüroğlu; Johan Vansteenkiste; David Spigel; James C.H. Yang; Hidenobu Ishii; Marina Garassino; Filippo de Marinis; Aleksandra Szczesna; Andreas Polychronis; Ruchan Uslu; Maciej Krzakowski; Jong-Seok Lee; Luana Calabrò; Osvaldo Arén Frontera; Huiling Xiong; Marcis Bajars; Mary Ruisi; Fabrice Barlesi is a Medicine article available to read on EtoBox.

What is Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial about?

## Introduction: In the javelin lung 200 trial, avelumab (anti-programmed death-ligand 1 [pd-l1] antibody) did not significantly prolong overall survival (os) versus docetaxel in patients with platinum-treated pd-l1+ nsclc. we report greater than 2-year follow-up data. ## Methods: Patients with stage iiib or iv or recurrent nsclc with disease progression after platinum-doublet chemotherapy were randomized 1:1 to avelumab 10 mg/kg every 2 weeks or docetaxel 75 mg/m every 3 weeks. the primary end point was os in patients with pd-l1+ tumors (greater than or equal to 1% tumor cell expression; ihc 73-10 pharmdx assay). ## Results: Of 792 patients, 529 had pd-l1+ tumors (264 versus 265 in the avelumab versus docetaxel arms, respectively). as of march 4, 2019, median duration of follow-up for os in the pd-l1+ population was 35.4 months in the avelumab arm and 34.7 months in the docetaxel arm; study treatment was ongoing in 25 (9.5%) versus 0 patients, respectively. in the pd-l1+ population, 2-year os rates (95% confidence interval [ci]) with avelumab versus docetaxel were 29.9% (24.5%-35.5%) versus 20.5% (15.6%-25.8%); in greater than or equal to 50% pd-l1+ subgroups, 2-year os rates were

Who reads Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial?

Author

Keunchil Park; Mustafa Özgüroğlu; Johan Vansteenkiste; David Spigel; James C.H. Yang; Hidenobu Ishii; Marina Garassino; Filippo de Marinis; Aleksandra Szczesna; Andreas Polychronis; Ruchan Uslu; Maciej Krzakowski; Jong-Seok Lee; Luana Calabrò; Osvaldo Arén Frontera; Huiling Xiong; Marcis Bajars; Mary Ruisi; Fabrice Barlesi

Publisher

Elsevier BV

Published

2021

Language

EN

Field

Medicine (Health Sciences)